Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Talampanel
Другие языки:

Talampanel

Подписчиков: 0, рейтинг: 0
Talampanel
Talampanel skeletal.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • (8R)-7-Acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.230.001
Chemical and physical data
Formula C19H19N3O3
Molar mass 337.379 g·mol−1
3D model (JSmol)
  • Nc4ccc(cc4)C(=NN2C(=O)C)c3cc1OCOc1cc3CC2C
  • InChI=1S/C19H19N3O3/c1-11-7-14-8-17-18(25-10-24-17)9-16(14)19(21-22(11)12(2)23)13-3-5-15(20)6-4-13/h3-6,8-9,11H,7,10,20H2,1-2H3/t11-/m1/s1 ☒N
  • Key:JACAAXNEHGBPOQ-LLVKDONJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Talampanel (INN; development codes GYKI 537773 and LY300164) is a drug which has been investigated for the treatment of epilepsy,malignant gliomas, and amyotrophic lateral sclerosis (ALS).

As of May 2010, results from the trial for ALS have been found negative. Talampanel is not currently under development.

Talampanel acts as a non-competitive antagonist of the AMPA receptor, a type of ionotropic glutamate receptor in the central nervous system.

It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.


Новое сообщение